Biologics have long represented the pinnacle of therapeutic complexity—antibodies, recombinant proteins, vaccines, and cell-based products that can alter the course of chronic and life-threatening diseases. Yet, as we enter the second quarter of the 21st century, the field is undergoing a major transformation. This change isn’t just about scale or yield—it’s about flexibility, speed, and programmability. Emerging tools […]